Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Renalytix PLC
Accounts Receivables
Renalytix PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Renalytix PLC
LSE:RENX
|
Accounts Receivables
$600k
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Craneware PLC
LSE:CRW
|
Accounts Receivables
$47.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
26%
|
CAGR 10-Years
18%
|
|
|
Cambridge Cognition Holdings PLC
LSE:COG
|
Accounts Receivables
£1.1m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-4%
|
|
|
Feedback PLC
LSE:FDBK
|
Accounts Receivables
£106k
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
Accounts Receivables
£1.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
P
|
Physitrack PLC
STO:PTRK
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
What is Renalytix PLC's Accounts Receivables?
Accounts Receivables
600k
USD
Based on the financial report for Dec 31, 2025, Renalytix PLC's Accounts Receivables amounts to 600k USD.
What is Renalytix PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-4%
The average annual Accounts Receivables growth rates for Renalytix PLC have been -10% over the past three years , -4% over the past five years .
